Amazing Results with Hydroxyurea Therapy in Chronic Hepatitis B: A Preliminary Report
Author | Hessam Hassanzadeh Kashani | en |
Author | Aliakbar Vossoughi | en |
Author | Peyman Adibi | en |
Author | Seyed Moayed Alavian | en |
Issued Date | 2010-09-30 | en |
Abstract | Background and Aims: To introduce the possible role of hydroxyurea (HU), a well-characterized antineoplastic drug with established antiviral effects, in the treatment of chronic hepatitis B. Methods: Four antiretroviral-naïve patients with chronic hepatitis B were enrolled in this limited pilot trial, and given 1000 mg/day of hydroxyurea for 4 weeks; then, the administration of the drug was suspended for 4 weeks. A clinical study and laboratory safety assessments and measurements of viral load were made at baseline, after drug therapy, and after one month suspension of the treatment. Results: All 4 patients showed a significant decrease in viral load after 4 weeks of hydroxyurea therapy and the viral load of 2 patients increased again after a 4-week suspension of hydroxyurea. Conclusions: Our data demonstrate that the old low-cost antineoplastic drug, hydroxyurea, efficiently blocks hepatitis B virus (HBV) replication. We suggest that HU will play an important role in the treatment of chronic hepatitis in the fore- seeable future. Further studies including those that evaluate optimal dosing in long-term use will continue to define the role of HU in the treatment of HBV infection alone or in combination with other antiviral drugs. | en |
DOI | https://doi.org/ | en |
Keyword | HBV | en |
Keyword | Chronic Hepatitis B | en |
Keyword | Hydroxyurea | en |
Keyword | Antiviral Therapy | en |
Publisher | Brieflands | en |
Title | Amazing Results with Hydroxyurea Therapy in Chronic Hepatitis B: A Preliminary Report | en |
Type | Brief Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 70525-pdf.pdf
- Size:
- 377.51 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF